Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)
Historic EBT Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 145.57%.
- Amylyx Pharmaceuticals' EBT Margin fell 1506800.0% to 145.57% in Q4 2024 from the same period last year, while for Sep 2025 it was 571.57%, marking a year-over-year decrease of 4527500.0%. This contributed to the annual value of 264.42% for FY2024, which is 2770000.0% down from last year.
- As of Q4 2024, Amylyx Pharmaceuticals' EBT Margin stood at 145.57%, which was down 1506800.0% from 17476.92% recorded in Q3 2024.
- In the past 5 years, Amylyx Pharmaceuticals' EBT Margin ranged from a high of 22.15% in Q2 2023 and a low of 17476.92% during Q3 2024
- Its 4-year average for EBT Margin is 3904.26%, with a median of 145.57% in 2024.
- Per our database at Business Quant, Amylyx Pharmaceuticals' EBT Margin skyrocketed by 98703100bps in 2023 and then crashed by -174969600bps in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' EBT Margin stood at 8120.0% in 2021, then skyrocketed by 98bps to 162.77% in 2022, then skyrocketed by 103bps to 5.11% in 2023, then tumbled by -2946bps to 145.57% in 2024.
- Its EBT Margin stands at 145.57% for Q4 2024, versus 17476.92% for Q3 2024 and 7106.55% for Q2 2024.